pipeline-prospector-insert
X

Find Clinical Drug Pipeline Developments & Deals for Alogliptin

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Alogliptin

            Therapeutic Area: Endocrinology Product Name: Nesina

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Celltrion

            Deal Size: $278.0 million Upfront Cash: $266.0 million

            Deal Type: Divestment June 11, 2020

            Details:

            The portfolio to be divested to Celltrion includes a variety of OTC products and pharmaceutical products such as Nesina® and Edarbi® and Products in a variety of indications.